Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Trial Profile

A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2018

At a glance

  • Drugs Perampanel (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 21 Nov 2018 According to an Eisai Inc media release, data will be presented at the upcoming American Epilepsy Society Annual Meeting taking place from November 30 to December 4, 2018 in New Orleans.
    • 06 Sep 2018 Planned End Date changed from 1 May 2019 to 1 Apr 2019.
    • 27 Apr 2018 Interim analysis (n=187; safety analysis set) results assessing retention rate, dosing experience, and safety with perampanel administered to epilepsy patients during routine clinical care, presented at the 70th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top